BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38387803)

  • 1. Development of a vestibular schwannoma tumor slice model for pharmacological testing.
    Nickl V; Fakler J; Ziebolz D; Rumpel C; Stabenow L; Bernhagen J; Rampeltshammer E; Ernestus RI; Löhr M; Gugel I; Matthies C; Monoranu CM; Hagemann C; Breun M
    J Neurosci Methods; 2024 May; 405():110082. PubMed ID: 38387803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.
    Paldor I; Abbadi S; Bonne N; Ye X; Rodriguez FJ; Rowshanshad D; Itzoe M; Vigilar V; Giovannini M; Brem H; Blakeley JO; Tyler BM
    J Neurooncol; 2017 Oct; 135(1):47-56. PubMed ID: 28735458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas.
    Kruyt IJ; Verheul JB; Hanssens PEJ; Kunst HPM
    J Neurosurg; 2018 Jan; 128(1):49-59. PubMed ID: 28128697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparable tumour microenvironment in sporadic and
    Gregory GE; Jones AP; Haley MJ; Hoyle C; Zeef LAH; Lin IH; Coope DJ; King AT; Evans DG; Paszek P; Couper KN; Brough D; Pathmanaban ON
    Brain Commun; 2023; 5(4):fcad197. PubMed ID: 37680691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas.
    Van Gompel JJ; Agazzi S; Carlson ML; Adewumi DA; Hadjipanayis CG; Uhm JH; Olson JJ
    Neurosurgery; 2018 Feb; 82(2):E52-E54. PubMed ID: 29309638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
    Agnihotri S; Gugel I; Remke M; Bornemann A; Pantazis G; Mack SC; Shih D; Singh SK; Sabha N; Taylor MD; Tatagiba M; Zadeh G; Krischek B
    J Neurosurg; 2014 Dec; 121(6):1434-45. PubMed ID: 25245477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The microenvironment in sporadic and neurofibromatosis type II-related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study.
    Lewis D; Donofrio CA; O'Leary C; Li KL; Zhu X; Williams R; Djoukhadar I; Agushi E; Hannan CJ; Stapleton E; Lloyd SK; Freeman SR; Wadeson A; Rutherford SA; Hammerbeck-Ward C; Evans DG; Jackson A; Pathmanaban ON; Roncaroli F; King AT; Coope DJ
    J Neurosurg; 2020 May; 134(5):1419-1429. PubMed ID: 32470937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response.
    Lim CY; Chang JH; Lee WS; Lee KM; Yoon YC; Kim J; Park IY
    Pancreatology; 2018 Dec; 18(8):913-927. PubMed ID: 30292644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of heterozygosity on chromosome 22 in sporadic schwannoma and its relation to the proliferation of tumor cells.
    Bian LG; Sun QF; Tirakotai W; Zhao WG; Shen JK; Luo QZ; Bertalanffy H
    Chin Med J (Engl); 2005 Sep; 118(18):1517-24. PubMed ID: 16232328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
    Plotkin SR; Allen J; Dhall G; Campian JL; Clapp DW; Fisher MJ; Jain RK; Tonsgard J; Ullrich NJ; Thomas C; Edwards LJ; Korf B; Packer R; Karajannis MA; Blakeley JO
    Neuro Oncol; 2023 Aug; 25(8):1498-1506. PubMed ID: 37010875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a newly established schwannoma cell line from a sporadic vestibular schwannoma patient.
    Xue L; He W; Wang Z; Chen H; Wang Z; Wu H
    Am J Transl Res; 2021; 13(8):8787-8803. PubMed ID: 34539995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Imaging in the Diagnosis and Management of Patients With Vestibular Schwannomas.
    Dunn IF; Bi WL; Mukundan S; Delman BN; Parish J; Atkins T; Asher AL; Olson JJ
    Neurosurgery; 2018 Feb; 82(2):E32-E34. PubMed ID: 29309686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates on Tumor Biology in Vestibular Schwannoma.
    Nourbakhsh A; Dinh CT
    Otolaryngol Clin North Am; 2023 Jun; 56(3):421-434. PubMed ID: 37121611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Biology and Microenvironment of Vestibular Schwannoma-Relation to Tumor Growth and Hearing Loss.
    Tesařová M; Peterková L; Šťastná M; Kolář M; Lacina L; Smetana K; Hynek R; Betka J; Vlasák A; Lukeš P; Fík Z
    Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.
    Ammoun S; Cunliffe CH; Allen JC; Chiriboga L; Giancotti FG; Zagzag D; Hanemann CO; Karajannis MA
    Neuro Oncol; 2010 Aug; 12(8):834-43. PubMed ID: 20511180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of sporadic and neurofibromatosis type 2-associated vestibular schwannoma growth in vitro and in vivo after treatment with the c-Jun N-terminal kinase inhibitor AS602801.
    Dougherty MC; Shibata SB; Clark JJ; Canady FJ; Yates CW; Hansen MR
    J Neurosurg; 2023 Apr; 138(4):962-971. PubMed ID: 36087315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vestibular Schwannoma Excision in Sporadic versus Neurofibromatosis Type 2 Populations.
    Mahboubi H; Maducdoc MM; Yau AY; Ziai K; Ghavami Y; Badran KW; Al-Thobaiti M; Brandon B; Djalilian HR
    Otolaryngol Head Neck Surg; 2015 Nov; 153(5):822-31. PubMed ID: 25791708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic landscape of sporadic vestibular schwannoma.
    Håvik AL; Bruland O; Myrseth E; Miletic H; Aarhus M; Knappskog PM; Lund-Johansen M
    J Neurosurg; 2018 Mar; 128(3):911-922. PubMed ID: 28409725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.
    Zhao Y; Liu P; Zhang N; Chen J; Landegger LD; Wu L; Zhao F; Zhao Y; Zhang Y; Zhang J; Fujita T; Stemmer-Rachamimov A; Ferraro GB; Liu H; Muzikansky A; Plotkin SR; Stankovic KM; Jain RK; Xu L
    Proc Natl Acad Sci U S A; 2018 Feb; 115(9):E2077-E2084. PubMed ID: 29440379
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.